温金华, 魏筱华, 程晓华, 左荣, 彭洪薇, 吕燕妮, 周健, 郑雪莲, 蔡军, 熊玉卿, 曹力. OATP1B1介导中药组分丹参素与瑞舒伐他汀的相互作用机制J. 药学学报, 2016,51(1): 75-79. doi: 10.16438/j.0513-4870.2015-0333
引用本文: 温金华, 魏筱华, 程晓华, 左荣, 彭洪薇, 吕燕妮, 周健, 郑雪莲, 蔡军, 熊玉卿, 曹力. OATP1B1介导中药组分丹参素与瑞舒伐他汀的相互作用机制J. 药学学报, 2016,51(1): 75-79. doi: 10.16438/j.0513-4870.2015-0333
WEN Jin-hua, WEI Xiao-hua, CHENG Xiao-hua, ZUO Rong, PENG Hong-wei, LÜ Yan-ni, ZHOU Jian, ZHENG Xue-lian, CAI Jun, XIONG Yu-qing, CAO Li. OATP1B1 in drug-drug interactions between traditional Chinese medicine Danshensu and rosuvastatinJ. Acta Pharmaceutica Sinica, 2016,51(1): 75-79. doi: 10.16438/j.0513-4870.2015-0333
Citation: WEN Jin-hua, WEI Xiao-hua, CHENG Xiao-hua, ZUO Rong, PENG Hong-wei, LÜ Yan-ni, ZHOU Jian, ZHENG Xue-lian, CAI Jun, XIONG Yu-qing, CAO Li. OATP1B1 in drug-drug interactions between traditional Chinese medicine Danshensu and rosuvastatinJ. Acta Pharmaceutica Sinica, 2016,51(1): 75-79. doi: 10.16438/j.0513-4870.2015-0333

OATP1B1介导中药组分丹参素与瑞舒伐他汀的相互作用机制

OATP1B1 in drug-drug interactions between traditional Chinese medicine Danshensu and rosuvastatin

  • 摘要: 本文探讨了基于药物转运体介导中药组分丹参素与瑞舒伐他汀相互作用的机制。首先初步探讨瑞舒伐他汀合用丹参素后瑞舒伐他汀在大鼠体内的药代动力学变化; 然后建立大鼠原代肝细胞模型, 探索丹参素对大鼠原代肝细胞摄取瑞舒伐他汀的影响, 最后利用慢病毒载体技术构建稳定表达OATP1B1*1aOATP1B1*5的HEK293T细胞模型, 探索丹参素对表达OATP1B1*1aOATP1B1*5的HEK293T细胞摄取瑞舒伐他汀的影响。合用丹参素后, 大鼠体内瑞舒伐他汀的药代动力学参数Cmax、AUC0-t、AUC0-∞分别增加约123%、194% 和195%, 而CLz/F值降低了60%; 20、40和80 μmol·L-1丹参素对肝细胞摄取瑞舒伐他汀均有抑制作用, 并使其摄取分别减少了3.13%、41.15% 和74.62%; 抑制参数IC50为 (53.04 ± 2.43) μmol·L-1。丹参素对OATP1B1介导瑞舒伐他汀转运的抑制作用与OATP1B1基因型有关, 对突变型OATP1B1*5的转运表现出明显的竞争抑制作用, 药物浓度为1和10 μmol·L-1时, 对OATP1B1*5转运瑞舒伐他汀分别减少了 (39.11 ± 4.94) % 和 (63.61 ± 3.94) %, 而当为野生型OATP1B1*1a时, 丹参素的抑制作用较轻, 1和10 μmol·L-1丹参素对OATP1B1*1a转运瑞舒伐他汀分别减少了 (8.22 ± 2.40) % 和 (11.56 ± 3.04) %。丹参素可显著影响瑞舒伐他汀在大鼠体内的药代动力学特征, 这与竞争抑制特异表达于肝细胞的OATP1B1介导瑞舒伐他汀的转运密切相关, 但由于OATP1B1基因突变导致其转运能力的改变, 丹参素只对OATP1B1*5介导瑞舒伐他汀转运表现出竞争抑制作用, 对OATP1B1*1a并无明显抑制作用。

     

    Abstract: The study was designed to explore the drug-drug interactions mechanisms mediated by OATP1B1 between traditional Chinese medicine Danshensu and rosuvastatin. First, the changes of rosuvastatin pharma­cokinetics were investigated in presence of Danshensu in rats. Then, the primary rat hepatocytes model was established to explore the effects of Danshensu on the uptake of rosuvastatin by hepatocytes. Finally, HEK293T cells with overexpression of OATP1B1*1a and OATP1B1*5 were established using a lentiviral delivery system to explore the effects of Danshensu on the uptake of rosuvastatin. Rosuvastatin pharmacokinetic parameters of Cmax, AUC0-t, AUC0-∞ were increased about 123%, 194% and 195%, by Danshensu in rats, while the CLz/F value was decreased by 60%. Uptake of rosuvastatin in the primary rat hepatocytes was decreased by 3.13%, 41.15% and 74.62%, respectively in the presence of 20, 40 and 80 μmol·L-1 Danshensu. The IC50 parameters was (53.04 ± 2.43) μmol·L-1. The inhibitory effect of Danshensu on OATP1B1 mediated transport of rosuvas­tatin was related to the OATP1B1 gene type. In OATP1B1*5-HEK293T mutant cells, transport of rosuvastatin were reduced by (39.11 ± 4.94) % and (63.61 ± 3.94) %, respectively, by Danshensu at 1 and 10 μmol·L-1. While transport of rosuvastatin was reduced by (8.22 ± 2.40) % and (11.56 ± 3.04) % and in OATP1B1*1a cells, respectively. Danshensu significantly altered the pharmacokinetics of rosuvastatin in rats, which was related to competitive inhibition of transport by OATP1B1. Danshensu exhibited a significant activity in the inhibition of rosuvastatin transport by OATP1B1*5-HEK293T, but not by OATP1B1*1a, suggesting a dependence on OATP1B1 sequence.

     

/

返回文章
返回